SAN DIEGO--(BUSINESS WIRE)--858 Therapeutics today announced an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California. The presentation will describe the preclinical characterization of ETX-19477, including potent antitumor activity in multiple animal models.
Presentation Details for AACR 2024
Abstract Number: 2083
Title: Discovery of ETX-19477, a novel and selective PARG inhibitor with high potency against tumors with underlying replication stress
Session Title: Novel Targets and Pathways
Session Date and Time: April 8, 2024, 9:00 AM – 12:30 PM (PDT)
About ETX-19477
The company’s lead asset, ETX-19477, is a novel and potent small molecule inhibitor of PARG, a glycohydrolase that plays a pivotal role in the regulation of DNA repair mechanisms and cooperates with PARP to carry out the single-strand break repair cycle. Pharmacological inhibition of PARG results in hyperPARylation, which leads to the death of cancer cells undergoing replication stress. In multiple animal models, ETX-19477 shows potent tumor growth inhibition, and its efficacy is associated with specific biomarker-defined tumors. A Phase I clinical trial is expected to start in the first half of 2024 in patients with advanced solid tumors at multiple sites in the U.S.
About 858 Therapeutics
858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule therapeutics directed against novel oncology targets. Its lead programs focus on important nodes in cancer biology, including DNA damage repair, innate immunity, and RNA epigenetics, and expand upon insights from over 20 years of work by the founders at predecessor companies. 858 Therapeutics is funded by leading biotechnology investors, including Versant Ventures, NEA, Cormorant Asset Management, and Logos Capital. 858 is headquartered in the biotech hub of San Diego, CA. For more information, please visit www.8five8tx.com.
